Gastroenterology

Spondyloarthritis

Questions discussed in this category

How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?

IgG4 manifestations include autoimmune pancreatitis and periaortic soft tissue mass.

2 Answers available

Which biologics are you comfortable combining with vedolizumab for spondyloarthritis or psoriatic arthritis patients in the setting of well-controlled inflammatory bowel disease?

2 Answers available

How do you treat celiac disease associated inflammatory arthritis refractory to gluten free diet?

1 Answer available

How do you approach screening for inflammatory bowel disease prior to starting IL-17 inhibitors?

1 Answer available

Would you use an IL-17 inhibitor for a psoriatic arthritis patient with inactive inflammatory bowel disease?

1 Answer available

Is it okay to use COX-2 selective NSAIDs in patients with IBD-associated arthritis when the IBD is in remission?

1 Answer available

Papers discussed in this category

Gut, 1999-04

Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses.

Gut, 2012-12

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Annals of the rheumatic diseases, 2019-04

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.

Ann Rheum Dis, 2014 Mar 21

The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study.

Lancet Gastroenterol Hepatol, 2023 Feb 01

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.

Dig Liver Dis, 2022 Aug 16

Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study.

Related Topics in Gastroenterology